publication date: Mar. 7, 2014


CL40-10c.html

By Conor Hale

Human papillomavirus vaccines are underused in the U.S. and need to be made a national public health priority, according to a report from the President’s Cancer Panel.

In a presentation to the National Cancer Advisory Board Feb. 27, panel chair Barbara Rimer outlined three goals to accelerate uptake of HPV vaccines, including having providers strongly encourage HPV vaccination to adolescents when other vaccines are being administered.

In 2012, only one-third of girls ages 13 to 17 completed the three-dose series. In some states, utilization was as low as 20 percent. About 71 percent and 60 percent of girls are vaccinated in Australia and the United Kingdom, respectively. The Department of Health and Human Services hopes to have 80 percent of girls complete the vaccination series as part of their Healthy People 2020 program.

The panel’s three goals included reducing missed clinical opportunities to recommend and administer HPV vaccines; increasing the public acceptance of the vaccines among parents, adolescents, and caregivers; and to maximize access to vaccination services, specifically by allowing pharmacists to administer vaccines to adolescents themselves. The report also focused on efforts to promote global uptake of the vaccine, especially in low- and middle-income countries.

The report, released Feb. 10, laid out objectives for payers to adequately reimburse providers for vaccination services, and to create a Healthy People 2020 goal for male vaccination rates. In 2012, 6.8 percent of boys ages 13 to 17 completed the three-dose series in the U.S., however the male vaccine was approved years later, according to the report.

“One of the … Continue reading 40-10 President’s Cancer Panel

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.